CD274 and urinary bladder carcinoma: This has led to the development of cancer immunotherapies addressing PD1–PDL1 interaction, like nivolumab, pembrolizumab, durvalumab, and atezolizumab, which have been already integrated into the treatment of some solid tumors as advanced renal cell carcinoma, non small cell lung cancer (NSCLC), bladder cancer, and melanoma.